RT Journal Article SR Electronic A1 Skarda, Jozef A1 Fridman, Eduard A1 Plevova, Pavlina A1 Hajduch, Marian A1 Radova, Lenka A1 Ofek, Efrat A1 Kopolovic, Jury A1 Kolek, Vitezslav A1 Kolar, Zdenek T1 PROGNOSTIC VALUE OF hMLH1 AND hMSH2 IMMUNOHISTOCHEMICAL EXPRESSION IN NON-SMALL CELL LUNG CANCER. A TISSUE MICROARRAY STUDY JF Biomedical papers YR 2006 VO 150 IS 2 SP 255 OP 259 DO 10.5507/bp.2006.037 UL https://biomed.papers.upol.cz/artkey/bio-200602-0010.php AB Background: hMLH1 and hMSH2 genes are both known to play a role in DNA mismatch repair. Nonetheless, the clinical significance of hMLH1 and hMSH2 protein expression in lung cancers remains unclear. Aim: The aim of this study was to investigate the immunohistochemical expression of hMLH1 and hMSH2 proteins in tumor specimens from 179 non-small cell lung cancer (NSCLC) patients using a tissue microarray technique and to correlate these results with other clinicopathological variables, including the disease specific and overall survivals. Method: hMLH1 and hMSH2 protein expression was evaluated by immunohistochemistry using monoclonal antibodies G168-728 for hMLH1 and FE11 for hMSH2 protein expression analysis. The Pearson χ<sup>2</sup> test was used to compare the hMLH1 and hMSH2 alterations among the cases and between various clinical and laboratory variables. P &lt; or = 0.05 was considered statistically significant. Results: Alteration of hMLH1 and hMSH2 protein expression was observed in 10 % of patients. No significant correlation was found between the protein expression and patient age, smoking status, tumor histology or disease stage and disease free and overall survival. Conclusions: Alterations in the expression of hMLH1 and hMSH2 proteins did not have any prognostic value in stage III. NSCLC patients.